Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Extended NICE drug-eluting stent consultation comes to an end:

This article was originally published in Clinica

Executive Summary

Next week sees the end of the extended consultation by the UK's National Institute for Health and Clinical Excellence (NICE) on NHS use of drug-eluting stents (DESs) to treat coronary artery disease. After allowing an extra month - to October 1 - for commenting on economic modelling data added to the consultation documentation on August 30 (two days after the original August 28 deadline - see Clinica No 1272, p 7), NICE's first appraisal committee meeting is now due to be held in November. Subject to any appeals process, the final guidance is scheduled for publication in March 2008.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049796

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel